Ramipril patient counseling information: Difference between revisions
Amr Marawan (talk | contribs) Created page with "__NOTOC__ {{Ramipril}} {{CMG}}; {{AE}} {{AM}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ALTACE (RAMIPRIL) CAPSULE [PFIZER LABORATORIES DIV P..." |
Amr Marawan (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AM}} | {{CMG}}; {{AE}} {{AM}} | ||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ALTACE (RAMIPRIL) CAPSULE [PFIZER LABORATORIES DIV PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0fc34cd8-86e6-4034-73bd-4263a68ba046 | publisher = | date = | accessdate = }}</ref> | ==Patient Counseling Information== | ||
====Angioedema==== | |||
[[Angioedema]], including laryngeal edema, can occur rarely with treatment with ACE inhibitors, especially following the first dose. Advise patients to report immediately any signs or symptoms suggesting angioedema (swelling of face, eyes, lips, or tongue, or difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician. | |||
====Neutropenia==== | |||
Advise patients to report promptly any indication of infection (e.g., [[sore throat]], [[fever]]), which could be a sign of [[neutropenia]]. | |||
====Symptomatic Hypotension==== | |||
Inform patients that [[light-headedness]] can occur, especially during the first days of therapy, and it should be reported. Advise patients to discontinue ALTACE if syncope (fainting) occurs, and to follow up with their health care providers. | |||
Inform patients that inadequate fluid intake or excessive perspiration, [[diarrhea]], or [[vomiting]] while taking ALTACE can lead to an excessive fall in blood pressure, with the same consequences of [[lightheadedness]] and possible [[syncope]]. | |||
====Pregnancy==== | |||
Female patients of childbearing age should be told about the consequences of exposure to Altace during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible. | |||
====Hyperkalemia==== | |||
Advise patients not to use salt substitutes containing [[potassium]] without consulting their physician.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ALTACE (RAMIPRIL) CAPSULE [PFIZER LABORATORIES DIV PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0fc34cd8-86e6-4034-73bd-4263a68ba046 | publisher = | date = | accessdate = }}</ref> | |||
Revision as of 17:51, 18 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2], Amr Marawan, M.D. [3]
For patient information about Ramipril, click here.
Ramipril
Overview
Ramipril tablet is an angiontensin converting enzyme inhibitor drug that is FDA approved for the treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy. Adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough. hypotension, rash, hyperkalemia, disorder of taste, cough.
Category
Antihypertensive Agents, Angiotensin Converting Enzyme Inhibitors. Editor-In-Chief: C. Michael Gibson, M.S., M.D. [4]; Associate Editor(s)-in-Chief: Amr Marawan, M.D. [5]
Patient Counseling Information
Angioedema
Angioedema, including laryngeal edema, can occur rarely with treatment with ACE inhibitors, especially following the first dose. Advise patients to report immediately any signs or symptoms suggesting angioedema (swelling of face, eyes, lips, or tongue, or difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician.
Neutropenia
Advise patients to report promptly any indication of infection (e.g., sore throat, fever), which could be a sign of neutropenia.
Symptomatic Hypotension
Inform patients that light-headedness can occur, especially during the first days of therapy, and it should be reported. Advise patients to discontinue ALTACE if syncope (fainting) occurs, and to follow up with their health care providers.
Inform patients that inadequate fluid intake or excessive perspiration, diarrhea, or vomiting while taking ALTACE can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope.
Pregnancy
Female patients of childbearing age should be told about the consequences of exposure to Altace during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.
Hyperkalemia
Advise patients not to use salt substitutes containing potassium without consulting their physician.[1]
References
Adapted from the FDA Package Insert.